This study determines whether a type of imaging scan called hyperpolarized 129-xenon magnetic resonance imaging (MRI) can help researchers check how lung impairment symptoms develop in patients receiving donor stem cell transplant who are at risk for lung-related side effects. Diagnostic procedures such as hyperpolarized 129-xenon MRI may help predict future lung function status in certain patients.
Additional locations may be listed on ClinicalTrials.gov for NCT05041140.
Locations matching your search criteria
United States
Texas
Houston
M D Anderson Cancer CenterStatus: Active
Contact: Ajay Sheshadri
Phone: 713-792-6238
PRIMARY OBJECTIVE:
I. To correlate hyperpolarized xenon 129 (129-xenon) measures of ventilation, gas exchange, and pulmonary circulation with spirometric and quantitative computed tomography (CT) measurements.
SECONDARY OBJECTIVES:
I. To assess the differences in 129-xenon (Xe) MRI characteristics between patients with and without bronchiolitis
obliterans syndrome (BOS) progression at 6 months after enrollment.
II. The assessment of the relationship of ventilation defect percentage (VDP), barrier defects (continuous variable), and circulation defects (continuous variable) with pulmonary function, quantitative CT measurements, St. George’s Respiratory Questionnaire (SGRQ), and SF-6D.
OUTLINE:
Patients and healthy volunteers receive 129-xenon via inhalation and undergo MRI over 30 minutes at baseline. Patients also complete the SGRQ and SF-6D questionnaires at baseline and at 6 months.
Trial PhaseNo phase specified
Trial TypeNot provided by clinicaltrials.gov
Lead OrganizationM D Anderson Cancer Center
Principal InvestigatorAjay Sheshadri
